Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients ...
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2014 /PRNewswire/ -- Tigercat Pharma, Inc. today announced positive results of a Phase 2 study evaluating the investigational oral NK-1 receptor antagonist VPD-737 ...
No comments:
Post a Comment